Jump to content

Clinical Trial - Charlie


tnmynatt

Recommended Posts

The insurance company has approved Charlie's appointment Tuesday at Vandy to get started with the clinical trial. He will be taking Targretin, which is a daily pill, which has been shown to be effective after Navelbine. It is not a chemo., but works some other way. I found this description on a web search:

Targretin ® (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs).

Ligand (Drug Co.) researchers believe that by binding to and activating RXR receptors, Targretin may help overcome a functional deficiency in tumor cells that is caused by low levels of RXR, and thereby delay tumor progression and improve survival.

It is already FDA approved for lymphoma. It is being tested with traditional chemo. and with the EGFR inhibitors. Matt posted (Thanks Matt) under "New Treatments...." about his clinical trial (http://lchelp.com/community/viewtopic.p ... =targretin), which is Targretin and Tarceva. Wish Charlie could get it in combination. But, we have to take what we can get. The ins. co. is so difficult.

Sorry if I bored you. This seems like a unique approach and wanted to share it with you.

Please pray for our safe trip (3 hrs. there, 3 hrs. back) on Tuesday and that nothing happens to keep him from getting started. Continuing to pray for you all and for a cure. Take care.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.